Analyst Price Targets — ZURA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 9, 2026 11:32 am | — | Wedbush | $15.00 | $6.01 | TheFly | Zura Bio initiated with an Outperform at Wedbush |
| April 3, 2025 10:12 am | Mitchell Kapoor | H.C. Wainwright | $3.00 | $1.09 | TheFly | Zura Bio price target lowered to $3 from $5 at H.C. Wainwright |
| November 8, 2024 6:47 pm | Yatin Suneja | Guggenheim | $15.00 | $4.58 | StreetInsider | Guggenheim Reiterates Buy Rating on Zura Bio Ltd. (ZURA) |
| September 5, 2024 6:09 am | Mitchell Kapoor | H.C. Wainwright | $5.00 | $3.95 | TheFly | Zura Bio initiated with a Neutral at H.C. Wainwright |
Latest News for ZURA
Zura Bio Limited (NASDAQ: ZURA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has assigned
Zura Bio Limited (NASDAQ: ZURA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has issued a
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported financial results for the full year ended December 31, 2025, and provided recent corporate updates. “2025 was…
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that the design of its ongoing Phase 2 TibuSURE clinical trial evaluating tibulizumab (ZB-106) in systemic…
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that members of its management team will participate in the following upcoming investor…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ZURA.
U.S. House Trading
No House trades found for ZURA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.